POSSIBLE LINK BETWEEN INSULIN GLARGINE AND CANCER QUESTIONED – MORE RESEARCH REQUIRED
Experts stress patients should not stop using insulin and consult their doctor if concerned. See This Week’s Item 1
Takeda’s Diabetes Drug Alogliptin Rejected by FDA
Asia’s biggest drugmaker, Takeda, failed to gain U.S. regulatory approval to market its new diabetes drug alogliptin because of insufficient data. The U.S. Food and Drug Administration issued a so-called complete-response letter saying the company must provide more data on cardiovascular risks. More information in next week’s issue.